{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:20:02Z","timestamp":1785284402656,"version":"3.55.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.vaccine.2022.10.056","type":"journal-article","created":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T16:57:02Z","timestamp":1669741022000},"page":"397-406","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["A randomized phase 3 trial to assess the immunogenicity and safety of 3 consecutively produced lots of freeze-dried MVA-BN\u00ae vaccine in healthy adults"],"prefix":"10.1016","volume":"41","author":[{"given":"Edgar","family":"Turner Overton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darja","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanja","family":"Vidojkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Menius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Nopora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Maclennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Weidenthaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.vaccine.2022.10.056_b0005","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1056\/NEJM198011273032204","article-title":"The confirmation and maintenance of smallpox eradication","volume":"303","author":"Breman","year":"1980","journal-title":"N England J Med"},{"issue":"3","key":"10.1016\/j.vaccine.2022.10.056_b0010","first-page":"397","article-title":"Smallpox: emergence, global spread, and eradication","volume":"15","author":"Fenner","year":"1993","journal-title":"Hist Philos Life Sci"},{"issue":"5\u20136","key":"10.1016\/j.vaccine.2022.10.056_b0015","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0147-9571(03)00025-0","article-title":"Smallpox vaccination and bioterrorism with pox viruses","volume":"26","author":"Mayr","year":"2003","journal-title":"Comp Immunol Microbiol Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2022.10.056_b0020","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1586\/14760584.7.8.1225","article-title":"Smallpox vaccines for biodefense: need and feasibility","volume":"7","author":"Artenstein","year":"2008","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2022.10.056_b0025","doi-asserted-by":"crossref","first-page":"257","DOI":"10.15585\/mmwr.mm6510a2","article-title":"Use of Vaccinia Virus Smallpox Vaccine in Laboratory and Health Care Personnel at Risk for Occupational Exposure to Orthopoxviruses - Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2015","volume":"65","author":"Petersen","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2022.10.056_b0030","unstructured":"Department of Defense. Update to clinical policy for the Department of Definse Smallpox Vaccination Program (memorandum), https:\/\/health.mil\/Reference-Center\/Policies\/2008\/04\/01\/Update-to-Clinical-Policy-for-the-Department-of-Defense-Smallpox-Vaccination-Program [accessed 19 Oct 2021]."},{"issue":"2","key":"10.1016\/j.vaccine.2022.10.056_b0035","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1093\/cid\/cit703","article-title":"Human monkeypox","volume":"58","author":"McCollum","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2022.10.056_b0040","doi-asserted-by":"crossref","first-page":"306","DOI":"10.15585\/mmwr.mm6710a5","article-title":"Emergence of Monkeypox - West and Central Africa, 1970\u20132017","volume":"67","author":"Durski","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"10.1016\/j.vaccine.2022.10.056_b0045","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1056\/NEJMoa032299","article-title":"The detection of monkeypox in humans in the Western Hemisphere","volume":"350","author":"Reed","year":"2004","journal-title":"N England J Med"},{"key":"10.1016\/j.vaccine.2022.10.056_b0050","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ijid.2018.11.008","article-title":"Monkeypox - Enhancing public health preparedness for an emerging lethal human zoonotic epidemic threat in the wake of the smallpox post-eradication era","volume":"78","author":"Petersen","year":"2019","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.10.056_b0055","unstructured":"Bunge EM, Hoet B, Chen L, et al. The changing epidemiology of human monkeypox\u2014a potential threat? A systematic review. PLoS Negl Trop Dis In press."},{"key":"10.1016\/j.vaccine.2022.10.056_b0060","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.antiviral.2018.11.004","article-title":"Vaccinating against monkeypox in the Democratic Republic of the Congo","volume":"162","author":"Petersen","year":"2019","journal-title":"Antiviral Res"},{"issue":"38","key":"10.1016\/j.vaccine.2022.10.056_b0065","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2018.23.38.1800509","article-title":"Two cases of monkeypox imported to the United Kingdom, September 2018","volume":"23","author":"Vaughan","year":"2018","journal-title":"Euro Surveill"},{"issue":"5","key":"10.1016\/j.vaccine.2022.10.056_b0070","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3201\/eid2505.190076","article-title":"Diagnosis of Imported Monkeypox, Israel, 2018","volume":"25","author":"Erez","year":"2019","journal-title":"Emerg Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2022.10.056_b0075","doi-asserted-by":"crossref","first-page":"782","DOI":"10.3201\/eid2604.191164","article-title":"Human-to-Human Transmission of Monkeypox Virus, United Kingdom, October 2018","volume":"26","author":"Vaughan","year":"2020","journal-title":"Emerg Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2022.10.056_b0080","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.jacc.2003.11.053","article-title":"Smallpox vaccination and myopericarditis: a clinical review","volume":"43","author":"Cassimatis","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.vaccine.2022.10.056_b0085","doi-asserted-by":"crossref","unstructured":"Engler RJ, Nelson MR, Collins LC, Jr., et al. A prospective study of the incidence of myocarditis\/pericarditis and new onset cardiac symptoms following smallpox and influenza vaccination. PloS one 2015;10(3):e0118283. DOI: 10.1371\/journal.pone.0118283.","DOI":"10.1371\/journal.pone.0118283"},{"issue":"5","key":"10.1016\/j.vaccine.2022.10.056_b0090","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.vaccine.2020.12.046","article-title":"Myopericarditis after vaccination, Vaccine Adverse Event Reporting System (VAERS), 1990\u20132018","volume":"39","author":"Su","year":"2021","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2022.10.056_b0095","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jacc.2004.05.004","article-title":"Incidence and follow-up of inflammatory cardiac complications after smallpox vaccination","volume":"44","author":"Eckart","year":"2004","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.vaccine.2022.10.056_b0100","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7205\/MILMED-D-12-00226","article-title":"Myopericarditis and pericarditis in the deployed military member: a retrospective series","volume":"178","author":"Lin","year":"2013","journal-title":"Mil Med"},{"key":"10.1016\/j.vaccine.2022.10.056_b0105","unstructured":"Bavarian Nordic. JYNNEOS Prescribing Information. 1 ed, 2019."},{"issue":"22","key":"10.1016\/j.vaccine.2022.10.056_b0110","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1016\/j.vaccine.2020.08.050","article-title":"The Brighton Collaboration standardized template for collection of key information for risk\/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform","volume":"39","author":"Volkmann","year":"2020","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2022.10.056_b0115","doi-asserted-by":"crossref","first-page":"e0138348","DOI":"10.1371\/journal.pone.0138348","article-title":"A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18\u201340 Year Old Subjects with Diagnosed Atopic Dermatitis","volume":"10","author":"Greenberg","year":"2015","journal-title":"PLoS ONE"},{"issue":"43","key":"10.1016\/j.vaccine.2022.10.056_b0120","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1016\/j.vaccine.2014.08.022","article-title":"Safety and immunogenicity of modified vaccinia Ankara as a smallpox vaccine in people with atopic dermatitis","volume":"32","author":"von Sonnenburg","year":"2014","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2022.10.056_b0125","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/infdis\/jis753","article-title":"Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects","volume":"207","author":"Greenberg","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.10.056_b0130","article-title":"Safety and immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic smallpox vaccine in vaccinia-naive and experienced human immunodeficiency virus-infected individuals: an open-label, controlled clinical phase II trial. Open Forum","volume":"2(2):ofv040","author":"Overton","year":"2015","journal-title":"Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2022.10.056_b0135","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1016\/j.vaccine.2020.01.058","article-title":"A randomized phase II trial to compare safety and immunogenicity of the MVA-BN smallpox vaccine at various doses in adults with a history of AIDS","volume":"38","author":"Overton","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.10.056_b0140","unstructured":"NCT01668537. A phase II trial to compare a liquid-frozen and a freeze-dried formulation of IMVAMUNE (MVA-BN) smallpox vaccine in vaccinia-na\u00efve healthy subjects, https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT01668537?term=POX-MVA&cond=Smallpox+%28Variola%29&draw=2&rank=6&view=results [accessed 01 Nov 2021]."},{"issue":"39","key":"10.1016\/j.vaccine.2022.10.056_b0145","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1016\/j.vaccine.2015.06.075","article-title":"Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-na\u00efve subjects","volume":"33","author":"Frey","year":"2015","journal-title":"Vaccine"},{"issue":"52","key":"10.1016\/j.vaccine.2022.10.056_b0150","doi-asserted-by":"crossref","first-page":"7442","DOI":"10.1016\/j.vaccine.2009.05.095","article-title":"Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain","volume":"27","author":"Suter","year":"2009","journal-title":"Vaccine"},{"issue":"23","key":"10.1016\/j.vaccine.2022.10.056_b0155","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1016\/j.vaccine.2014.02.043","article-title":"Phase II randomized, double-blinded comparison of a single high dose (5\u00d710(8) TCID50) of modified vaccinia Ankara compared to a standard dose (1\u00d710(8) TCID50) in healthy vaccinia-na\u00efve individuals","volume":"32","author":"Frey","year":"2014","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2022.10.056_b0160","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.vaccine.2009.11.030","article-title":"A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE","volume":"28","author":"von Krempelhuber","year":"2010","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2022.10.056_b0165","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.vaccine.2005.11.022","article-title":"Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine","volume":"24","author":"Vollmar","year":"2006","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2022.10.056_b0170","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.biologicals.2014.05.007","article-title":"Vaccine instability in the cold chain: mechanisms, analysis and formulation strategies","volume":"42","author":"Kumru","year":"2014","journal-title":"Biologicals : journal of the International Association of Biological Standardization"},{"issue":"42","key":"10.1016\/j.vaccine.2022.10.056_b0175","doi-asserted-by":"crossref","first-page":"5507","DOI":"10.1016\/j.vaccine.2015.08.085","article-title":"Freeze-drying of live virus vaccines: A review","volume":"33","author":"Hansen","year":"2015","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2022.10.056_b0180","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.3390\/v7041726","article-title":"The evolution of poxvirus vaccines","volume":"7","author":"Sanchez-Sampedro","year":"2015","journal-title":"Viruses"},{"issue":"7","key":"10.1016\/j.vaccine.2022.10.056_b0185","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.4161\/hv.24319","article-title":"Unintentional transfer of vaccinia virus associated with smallpox vaccines: ACAM2000((R)) compared with Dryvax((R))","volume":"9","author":"Tack","year":"2013","journal-title":"Hum Vaccin Immunother"},{"issue":"17","key":"10.1016\/j.vaccine.2022.10.056_b0190","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/j.vaccine.2016.11.097","article-title":"The origins of the vaccine cold chain and a glimpse of the future","volume":"35","author":"Lloyd","year":"2017","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22013330?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22013330?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:20:46Z","timestamp":1759404046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22013330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0264410X22013330"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.10.056","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized phase 3 trial to assess the immunogenicity and safety of 3 consecutively produced lots of freeze-dried MVA-BN\u00ae vaccine in healthy adults","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.10.056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}